Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2013 | 12-2012 | 09-2012 | 06-2012 | 03-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,170 | -12,568 | -10,647 | -8,300 | -4,468 |
| Depreciation Amortization | 169 | 677 | 508 | 339 | 169 |
| Accounts payable and accrued liabilities | -194 | 142 | 180 | 88 | 212 |
| Other Working Capital | -358 | 249 | 1,676 | 1,388 | 610 |
| Other Operating Activity | 1,576 | 241 | 358 | 790 | 687 |
| Operating Cash Flow | $-2,976 | $-11,259 | $-7,926 | $-5,696 | $-2,790 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -16 | -16 | -16 | -16 |
| Investing Cash Flow | $N/A | $-16 | $-16 | $-16 | $-16 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 3,523 | 4,791 | 2,078 | 2,078 | N/A |
| Other Financing Activity | 2,550 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $6,073 | $4,791 | $2,078 | $2,078 | $N/A |
| Beginning Cash Position | 1,222 | 7,706 | 7,706 | 7,706 | 7,706 |
| End Cash Position | 4,318 | 1,222 | 1,842 | 4,072 | 4,900 |
| Net Cash Flow | $3,096 | $-6,484 | $-5,864 | $-3,634 | $-2,806 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,976 | -11,259 | -7,926 | -5,696 | -2,790 |
| Capital Expenditure | N/A | -16 | -16 | -16 | -16 |
| Free Cash Flow | -2,976 | -11,275 | -7,942 | -5,712 | -2,806 |